Updated Guideline: Screening for Anal Dysplasia and Cancer in Adults With HIV

Updated by lead author Dr. Bruce Hirsch, with the Medical Care Criteria Committee, the Screening for Anal Dysplasia and Cancer in Adults With HIV guideline aims to inform clinicians in New York State who provide primary care to individuals with HIV about human papillomavirus (HPV)-related anal disease and assist them in identifying opportunities for its prevention, screening, and treatment.

Updates to the guideline include:

• Global:
• Discussion and citations added of 2024 consensus guidelines on anal cancer screening published by the International Anal Neoplasia Society and U.S. Department of Health and Human Services
• Epidemiologic data and citations updated
• Screening for Anal Disease section:
• Recommendations on the timing of anal cancer screening by age and population revised
• Table 1 added to outline acceptable anal cancer screening strategies, their specificity and sensitivity, and their benefits and limitations
• Follow-Up of Abnormal Anal Cancer Screening Results section: Figure 1 revised to include algorithms detailing appropriate follow-up for all anal cancer screening strategies
• Treatment and Follow-Up section: Recommendation on follow-up of patients with a history of high-grade squamous intraepithelial lesions revised

Go to the guideline

Contents:

• Purpose of This Guideline
• HPV-Related Anal Disease in Individuals With HIV
• HPV Prevention
• Screening for Anal Disease
• Follow-Up of Abnormal Anal Cancer Screening Results
• Treatment and Follow-Up
• All Recommendations
• Printable PDF
• Pocket Guide
• Slide Set

Related guidelines:

• Prevention and Management of Human Papillomavirus Infection in Adults With HIV
• Screening for Cervical Dysplasia and Cancer in Adults With HIV

Hot Topics

• Clinical Guidelines Program: U.S. Government Web Pages May Not Be Available
• NYSDOH: Measles Public Service Announcement
• NYSDOH: Measles for Health Care Providers
• NYSDOH AI: Congenital Syphilis Elimination Framework Discussion Forums
• NYCDOH&MH: Providing Comprehensive Care to Women Who Have Sex With Women
• New York State: Q&A Guidance to Private and Non-Profit Organizations and Entities on Evaluating How to Respond to Requests From Federal Immigration Authorities

See all Hot Topics

Don't Miss

The Role of Opioid Treatment Programs in Hepatitis C Care: A Path to Elimination: Between 2010 and 2022 (the latest year for which data are available), 194,375 New Yorkers were diagnosed with hepatitis C (HCV) and of those, 53% (103,213 individuals) are known to have cleared their infection either through treatment or spontaneously. This statistic is worth celebrating, but also highlights the ongoing need for action—the goal outlined in New York State’s Hepatitis C Elimination Plan is to reach 80% by 2030. Furthermore, people who inject drugs are disproportionally affected by HCV—in 2022, 48% of newly reported cases of acute HCV in New York indicated injection drug use as a risk factor. And, when analyzing cases with known risk factors, that figure rose to 81% of newly reported acute cases indicating injection drug use. Providing HCV treatment in opioid treatment programs (OTPs) is an innovative and necessary strategy to curb the ongoing epidemic and achieve statewide goals for elimination.

This episode features Abigail Hunter, MPH, MSN, FNP-BC, sharing her experience providing HCV treatment at an OTP and recommendations for listeners interested in integrating treatment into clinical services. Listen Now

CEI:

• 3/13: Achieved SVR, What’s Next? Hepatitis C Post-treatment Outcomes and Management
• 3/17: Trauma Informed Care for People Who Use Drugs
• 3/19: This Month in HIV: HIV Prevention and Treatment for All Women
• 3/21: Integrating Harm Reduction into Every Clinical Encounter
• 4/2: READit – Journal Club with the Sexual Health Center
• 5/2: 11th Annual NYS Sexual Health Conference

See all

General:

• 3/19: Mountain West AETC: Addiction Medicine Webinar: Addressing SUD, Homelessness in Primary and Low Barrier Care Settings
• 3/20: Northeast/Caribbean AETC: Paying for HIV Care in NYS Part 1
• 3/21: Pacific AETC: Black Men’s HIV Leadership Capacity Building Initiative
• 3/27: New England AETC: Medical Case Manager ECHO: Motivational Interviewing Session
• 4/2: New England AETC: Intimate Partner Violence and HIV ECHO: HIV Criminalization and IPV
• 4/4: NAHEWD: Integrating Substance Use Disorder Treatment With HIV Care: Inclusive Strategies for Immigrant Communities
• 4/7: NYSDOH AI: Congenital Syphilis Elimination Framework Discussion Forum: Clinical Providers
• 4/24: ASAM 56th Annual Conference – Innovations in Addiction Medicine and Science
• 4/24: New England AETC: Medical Case Manager ECHO: Motivational Interviewing Session
• 4/29: The NaLa Conference
• 5/1: ACTHIV 2025, the 19th Annual American Conference for the Treatment of HIV
• 5/7: New England AETC: Intimate Partner Violence and HIV ECHO: Maternal Mortality in CT and IPV
• 5/14: 3rd Annual New York State Hepatitis C Elimination Progress Report Virtual Meeting
• 5/19: NYSDOH AI: Congenital Syphilis Elimination Framework Discussion Forum: Non-Clinical Providers
• 5/22: New England AETC: Medical Case Manager ECHO: Motivational Interviewing Session
• 6/18: Mountain West AETC: Addiction Medicine Webinar: Substance Use and HIV
• 6/25: NYSDOH AI: Congenital Syphilis Elimination Framework Discussion Forum: Public Sector
• 7/13: IAS 2025, the 13th IAS Conference on HIV Science
• 8/6: NYSDOH AI: Congenital Syphilis Elimination Framework Discussion Forum: Medical Societies & Guidance Communities
• 9/29: NYSDOH AI: Congenital Syphilis Elimination Framework Discussion Forum: Private Sector
• 10/29: NYSDOH AI: Congenital Syphilis Elimination Framework Discussion Forum: Clinical & Non-Clinical Providers

See all